Competition between IL-1, IL-1ra and TGF-β1 modulates the response of the ELA4.NOB-1/CTLL bioassay: Implications for clinical investigations

Paul Ashwood, R. Harvey, T. Verjee, R. Wolstencroft, R. P H Thompson, J. J. Powell

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objectives: The use of ELISA techniques to measure cytokine levels in clinical samples has chiefly replaced more labour intensive bioassays. ELISA measurements, however, do not reflect the functional activity of a cytokine within a sample; interleukin-1 (IL-1), for example, has two agonist isoforms (IL-1α and IL-1β) and a competitive receptor antagonist (IL-1ra), and can be regulated by transforming growth factor β1 (TGF-β1). The net effect of these cytokines, rather than IL-1 levels, are frequently suggested to regulate tissue inflammation, but confirming this has been difficult. Methods: We used the ELA4.NOB-1/CTLL co-culture IL-1 bioassay to investigate whether IL-1 activity was inhibited by IL-1ra and TGF-β1 in a predictable manner. Results: Thymidine incorporation into CTLL cells, induced by IL-1, was reduced dose dependently by IL-1ra and TGF-β1. With optimal levels of IL-1 CTLL responsiveness was reduced by 90% by 1 ng/ml TGF-β1 and completely abolished by 100 ng/ml IL-1ra. As expected, TGF-β1 and IL-1ra had independent mechanisms of action on the bioassay cell lines, and, in combination, they caused an additive, but not synergistic, effect. Importantly, the effect of these cytokines could be completely abolished in the presence of neutralising antibodies. Conclusions: Bioassay should provide specific functional information on the net IL-1 activity of clinical samples, while the use of specific antibodies could ascertain the contribution of individual cytokines within such samples.

Original languageEnglish (US)
Pages (from-to)60-65
Number of pages6
JournalInflammation Research
Volume53
Issue number2
DOIs
StatePublished - Feb 2004
Externally publishedYes

Fingerprint

Interleukin 1 Receptor Antagonist Protein
Bioassay
Transforming Growth Factors
Interleukin-1
Biological Assay
Cytokines
Enzyme-Linked Immunosorbent Assay
Coculture Techniques
Neutralizing Antibodies
Thymidine
Protein Isoforms
Cells
Personnel
Tissue
Inflammation
Cell Line

Keywords

  • Bioassay
  • ELISA
  • Interleukin 1
  • Interleukin 1 receptor antagonist
  • Transforming growth factor β1

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology (medical)
  • Immunology
  • Cell Biology

Cite this

Competition between IL-1, IL-1ra and TGF-β1 modulates the response of the ELA4.NOB-1/CTLL bioassay : Implications for clinical investigations. / Ashwood, Paul; Harvey, R.; Verjee, T.; Wolstencroft, R.; Thompson, R. P H; Powell, J. J.

In: Inflammation Research, Vol. 53, No. 2, 02.2004, p. 60-65.

Research output: Contribution to journalArticle

Ashwood, Paul ; Harvey, R. ; Verjee, T. ; Wolstencroft, R. ; Thompson, R. P H ; Powell, J. J. / Competition between IL-1, IL-1ra and TGF-β1 modulates the response of the ELA4.NOB-1/CTLL bioassay : Implications for clinical investigations. In: Inflammation Research. 2004 ; Vol. 53, No. 2. pp. 60-65.
@article{fb9c032a59eb4222a68d66aa20864268,
title = "Competition between IL-1, IL-1ra and TGF-β1 modulates the response of the ELA4.NOB-1/CTLL bioassay: Implications for clinical investigations",
abstract = "Objectives: The use of ELISA techniques to measure cytokine levels in clinical samples has chiefly replaced more labour intensive bioassays. ELISA measurements, however, do not reflect the functional activity of a cytokine within a sample; interleukin-1 (IL-1), for example, has two agonist isoforms (IL-1α and IL-1β) and a competitive receptor antagonist (IL-1ra), and can be regulated by transforming growth factor β1 (TGF-β1). The net effect of these cytokines, rather than IL-1 levels, are frequently suggested to regulate tissue inflammation, but confirming this has been difficult. Methods: We used the ELA4.NOB-1/CTLL co-culture IL-1 bioassay to investigate whether IL-1 activity was inhibited by IL-1ra and TGF-β1 in a predictable manner. Results: Thymidine incorporation into CTLL cells, induced by IL-1, was reduced dose dependently by IL-1ra and TGF-β1. With optimal levels of IL-1 CTLL responsiveness was reduced by 90{\%} by 1 ng/ml TGF-β1 and completely abolished by 100 ng/ml IL-1ra. As expected, TGF-β1 and IL-1ra had independent mechanisms of action on the bioassay cell lines, and, in combination, they caused an additive, but not synergistic, effect. Importantly, the effect of these cytokines could be completely abolished in the presence of neutralising antibodies. Conclusions: Bioassay should provide specific functional information on the net IL-1 activity of clinical samples, while the use of specific antibodies could ascertain the contribution of individual cytokines within such samples.",
keywords = "Bioassay, ELISA, Interleukin 1, Interleukin 1 receptor antagonist, Transforming growth factor β1",
author = "Paul Ashwood and R. Harvey and T. Verjee and R. Wolstencroft and Thompson, {R. P H} and Powell, {J. J.}",
year = "2004",
month = "2",
doi = "10.1007/s00011-003-1220-6",
language = "English (US)",
volume = "53",
pages = "60--65",
journal = "Inflammation Research",
issn = "1023-3830",
publisher = "Birkhauser Verlag Basel",
number = "2",

}

TY - JOUR

T1 - Competition between IL-1, IL-1ra and TGF-β1 modulates the response of the ELA4.NOB-1/CTLL bioassay

T2 - Implications for clinical investigations

AU - Ashwood, Paul

AU - Harvey, R.

AU - Verjee, T.

AU - Wolstencroft, R.

AU - Thompson, R. P H

AU - Powell, J. J.

PY - 2004/2

Y1 - 2004/2

N2 - Objectives: The use of ELISA techniques to measure cytokine levels in clinical samples has chiefly replaced more labour intensive bioassays. ELISA measurements, however, do not reflect the functional activity of a cytokine within a sample; interleukin-1 (IL-1), for example, has two agonist isoforms (IL-1α and IL-1β) and a competitive receptor antagonist (IL-1ra), and can be regulated by transforming growth factor β1 (TGF-β1). The net effect of these cytokines, rather than IL-1 levels, are frequently suggested to regulate tissue inflammation, but confirming this has been difficult. Methods: We used the ELA4.NOB-1/CTLL co-culture IL-1 bioassay to investigate whether IL-1 activity was inhibited by IL-1ra and TGF-β1 in a predictable manner. Results: Thymidine incorporation into CTLL cells, induced by IL-1, was reduced dose dependently by IL-1ra and TGF-β1. With optimal levels of IL-1 CTLL responsiveness was reduced by 90% by 1 ng/ml TGF-β1 and completely abolished by 100 ng/ml IL-1ra. As expected, TGF-β1 and IL-1ra had independent mechanisms of action on the bioassay cell lines, and, in combination, they caused an additive, but not synergistic, effect. Importantly, the effect of these cytokines could be completely abolished in the presence of neutralising antibodies. Conclusions: Bioassay should provide specific functional information on the net IL-1 activity of clinical samples, while the use of specific antibodies could ascertain the contribution of individual cytokines within such samples.

AB - Objectives: The use of ELISA techniques to measure cytokine levels in clinical samples has chiefly replaced more labour intensive bioassays. ELISA measurements, however, do not reflect the functional activity of a cytokine within a sample; interleukin-1 (IL-1), for example, has two agonist isoforms (IL-1α and IL-1β) and a competitive receptor antagonist (IL-1ra), and can be regulated by transforming growth factor β1 (TGF-β1). The net effect of these cytokines, rather than IL-1 levels, are frequently suggested to regulate tissue inflammation, but confirming this has been difficult. Methods: We used the ELA4.NOB-1/CTLL co-culture IL-1 bioassay to investigate whether IL-1 activity was inhibited by IL-1ra and TGF-β1 in a predictable manner. Results: Thymidine incorporation into CTLL cells, induced by IL-1, was reduced dose dependently by IL-1ra and TGF-β1. With optimal levels of IL-1 CTLL responsiveness was reduced by 90% by 1 ng/ml TGF-β1 and completely abolished by 100 ng/ml IL-1ra. As expected, TGF-β1 and IL-1ra had independent mechanisms of action on the bioassay cell lines, and, in combination, they caused an additive, but not synergistic, effect. Importantly, the effect of these cytokines could be completely abolished in the presence of neutralising antibodies. Conclusions: Bioassay should provide specific functional information on the net IL-1 activity of clinical samples, while the use of specific antibodies could ascertain the contribution of individual cytokines within such samples.

KW - Bioassay

KW - ELISA

KW - Interleukin 1

KW - Interleukin 1 receptor antagonist

KW - Transforming growth factor β1

UR - http://www.scopus.com/inward/record.url?scp=1242306734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242306734&partnerID=8YFLogxK

U2 - 10.1007/s00011-003-1220-6

DO - 10.1007/s00011-003-1220-6

M3 - Article

C2 - 15021970

AN - SCOPUS:1242306734

VL - 53

SP - 60

EP - 65

JO - Inflammation Research

JF - Inflammation Research

SN - 1023-3830

IS - 2

ER -